Matthias Bodenstedt - 22 Jun 2026 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: MLTX
Reported as of: 22 Jun 2026
Net transaction value: -$862,205
SEC form: 4
Accepted by SEC: 23 Jun 2026, 16:01:08 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt

Key filing fact

Matthias Bodenstedt filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 23 Jun 2026.

Key facts

This page summarizes Matthias Bodenstedt's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 16:01.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: -$862,205.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001920545 Primary reporting owner

Bodenstedt Matthias

Relationship: Chief Financial Officer
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Sale

Transaction value: $862,205
Shares: -39,120
Change %: -3.4%
Price: $22.04
Shares after: 1,115,435
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.